Clinical Trials

Our on-going research studies provide an opportunity to have your child, your adolescent, or yourself thoroughly screened for ADHD at no cost to you. Screening procedures will vary depending upon the type of study being conducted. If you meet diagnostic criteria for ADHD and inclusion criteria for one or more studies, you may be eligible to receive medication for the treatment of ADHD at no cost to you.

Neurobiological Basis of Response to Guanfacine Extended Release in Children and Adolescents with ADHD: An fMRI Study of Brain Activation Pre- and Post- Treatment

Location: Mount Sinai Health System, New York, NY
Sponsor: Shire Pharmaceuticals Inc.

Description:

Dr. Jeffrey Newcorn and his team at the Clinical Trials Program are evaluating brain activation in response to Guanfacine, a medication used in the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Please call if your child is between 8-15 years of age and experiences symptoms of ADHD, like being easily distracted, making careless mistakes, being forgetful in daily activities, having difficulty paying attention, and difficulty organizing.

Your child will receive at no cost: a comprehensive psychiatric and physical screening to determine whether he or she has ADHD and is healthy enough to be treated with medication; pre-and post-treatment fMRI scanning; weekly visits with our physicians; up to 2 months of medication (either during the trial or, if assigned to placebo, after 6 to 8 weeks of participation; referral for on-going care with progress report of participation.

The study last up to 9 weeks, but you may choose to see our doctors at no cost for up to 2 additional months while your child is stabilized on the medication that works best for him or her.

Reimbursement is available to participants and their parents.

If we do not have a research study that is right for you at this time, we can refer you with other options and/or contact you for future studies. 

GCO# 09-1825 IRB approved 11-3-2012 to 11-2-2014

Contact:
Beth Krone, PhD
Tel: 212-241-8012
E-mail: beth.krone@mssm.edu

Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network Based Approach

Our recent work on the study Methylphenidate and Atomoxetine in ADHD: fMRI Measures of Mechanisms and Response produced exciting findings, offering a window into the common and unique neurophysiological mechanisms of response to stimulant and non-stimulant treatments. To enhance the interpretation and clinical utility of these results, we are conducting an in-depth investigation of the impact of the two treatments on relevant neural networks, and evaluating whether improvement is achieved via normalization or other adaptive changes in brain function. As participants in the study: Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network Based Approach, healthy youth and youth with ADHD will participate in fMRI brain scanning while performing neuropsychological tasks. Only youth with ADHD will be randomized to one of the medication treatment groups. Youth receiving medication will be carefully monitored during weekly visits with our study physicians during the 6-8 week duration of participation.

Location: Mount Sinai Health System, New York, NY
Sponsor: NIH

GCO# 11-0161 IRB approved 12-7-2012 to 4-30-2014

Contact:
Beth Krone, PhD or Anne Claude Bedard, PhD
Tel: 212-241-8012
E-mail: beth.krone@mssm.edu or ac.bedard@mssm.edu

Neurobiological Basis of Response to Vyvanse in Adults with ADHD: An fMRI Study of Brain Activation Pre- and Post- Treatment

Dr. Jeffrey Newcorn and his team at the Clinical Trials Program are evaluating brain activation in response to Vyvanse, a medication used in the treatment of Adults with Attention Deficit Hyperactivity Disorder (ADHD).
Please call if you are between 18-55 years of age and experiences symptoms of ADHD, like being easily distracted, making careless mistakes, being forgetful in daily activities, having difficulty paying attention, and difficulty organizing.

The study involves no cost: a comprehensive psychiatric and physical screening to determine whether you have ADHD; pre-and post-treatment fMRI scanning; weekly visits with our physicians; about two months of medication; referral for on-going care with progress report of participation.

A small stipend is provided.

Location: Mount Sinai Health System, New York, NY
Sponsor: Shire Pharmaceuticals Inc.

GCO# 09-1186 IRB approved to 3-24-2014

Contact:
Beth Krone, PhD or Stephanie Duhoux, PhD
Tel: 212-241-7009
E-mail: beth.krone@mssm.edu or stephanie.duhoux@mssm.edu

A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Forced-dose Titration, Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)

BRANY IRB 12-10-190

Contact:
Beth Krone, PhD or Stephanie Duhoux, PhD
Tel: 212-241-8012 or 212-241-7009
E-mail: beth.krone@mssm.edu or stephanie.duhoux@mssm.edu

A Phase 4, Randomized, Double-blind, Multicenter, Parallel-group, Active-controlled, Dose optimization Safety and Efficacy Study of SPD489 (VYVANSE®) Compared with OROS-MPH (CONCERTA®) with a Placebo Reference Arm, in Adolescents Aged 13-17 Years with Attention-deficit/Hyperactivity Disorder (ADHD)

BRANY IRB 12-10-189

Contact:
Beth Krone, PhD or Stephanie Duhoux, PhD
Tel: 212-241-8012 or 212-241-7009
E-mail: beth.krone@mssm.edu or stephanie.duhoux@mssm.edu


Contact Us

For more information about participation in research
Tel.: 212-241-8012
Send e-mail

For more information about ADHD Center Clinical Programs
Tel.: 212-241-4423
Send e-mail 

For more information about Learning Disorders
Tel.: 212-241-4423
Send e-mail

Center of Excellence for ADHD and Related Disorders
Icahn School of Medicine
Department of Psychiatry
One Gustave L. Levy Place
Box 1230
New York, NY 10029